Scientists probe whether West Africa s recent Ebola outbreak was from man who survived epidemic five years ago localnews8.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from localnews8.com Daily Mail and Mail on Sunday newspapers.
1.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review.
2.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention.
3.
Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19).
4.
Shah AS, Wong AW, Hague CJ, et al. A prospective study of 12-week respiratory outcomes in COVID-19–related hospitalisations.
5.
Wei J, Yang H, L
This edited book provides a first overview of how populist parties responded to the COVID-19 pandemic crisis in Europe. Although populism would normally benefit from crisis situations (e.g., political representation or economic crises), the peculiar nature of this health crisis does not make the benefit obvious. For it to be exploited, a crisis must be politicized. While populists have tried to take advantage of the crisis situation, the impossibility of taking ownership of the COVID-19 issue has made the crisis hard to be exploited. In particular, populists in power have tried to depoliticize the pandemic, whereas radical right-populists in opposition tried to politicize the crisis, though failing to gain the relevant public support. This book considers populist parties in eight European democracies, providing a framework of analysis for their responses to the COVID-19 crisis. It does so by engaging with the literature on crisis and populism from a theoretical perspective and throug
Hepatitis B virus infection and associated risk factors among medical students in eastern Ethiopia
Tewodros Tesfa , Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing
Behailu Hawulte, Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing – original draft, Writing – review & editing
Affiliation Public Health and Policy Unit, School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia Roles Data curation, Formal analysis, Resources, Software, Validation
Article content
MELBOURNE, Australia and INDIANAPOLIS, Jan. 24, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that the first patients have been dosed in the Phase III ZIRCON
1 clinical trial of Telix’s renal cancer diagnostic imaging product TLX250-CDx (
89Zr-girentuximab) in the United States.
The objective of the ZIRCON trial is to evaluate the sensitivity and specificity of PET/CT imaging with TLX250-CDx to non-invasively detect clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses in comparison with surgical resection (histology), as the standard of truth.
The ZIRCON trial, which includes twelve participating clinical study sites across the U.S. and Canada, initiated patient recruitment in U.S. on Friday, with the first patients being dosed with TLX250-CDx at University of California, Los Angeles (UCLA), and Seattle Cancer Care Alliance, University of Washington, Seattle (SCCA)